Sign In
Buy EVFM
$0.0080
+0.0015 (+23.08%)
At Close: Jun 03, 2026
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
09:18am, Thursday, 11'th Sep 2025
-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) -- -- PHEXXI® is #1 most follow
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
09:28am, Tuesday, 09'th Sep 2025
-- Special Meeting to be held on September 26, 2025 -- SAN DIEGO , Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM)
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
08:56am, Thursday, 21'st Aug 2025
-- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide
-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a new
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
08:46am, Thursday, 14'th Aug 2025
-- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Bec
Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference
08:46am, Tuesday, 05'th Aug 2025
SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier , will be honored with the Trailblazing Female Founders Award�
Evofem's PHEXXI Submitted for Marketing Approval in United Arab Emirates by Pharma 1 Drug Store
08:47am, Monday, 23'rd Jun 2025
— Pharma 1 Will Place Launch Quantity Order for PHEXXI in July 2025 — — Commercial Launch in UAE Targeted for Q1 2026 — SAN DIEGO , June 23, 2025 /PRNewswire/ -- Women's health innovator Evof
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
08:15am, Monday, 09'th Jun 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the app
Evofem Signs SOLOSEC License Agreement for Middle East with Pharma 1
08:59am, Wednesday, 21'st May 2025
— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis — SAN DIEGO , May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Bios
Evofem Reports First Quarter 2025 Financial Results and Provides Business Update
07:59am, Thursday, 15'th May 2025
SAN DIEGO , May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. "Quarterly fl
Evofem Biosciences to Present at Emerging Growth Conference
08:41am, Monday, 14'th Apr 2025
SAN DIEGO , April 14, 2025 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming Emerging Growth Conference as follo
Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics
08:47am, Wednesday, 26'th Mar 2025
-- Evofem's Cost to Manufacture PHEXXI will Decrease by 55% - 60% -- SAN DIEGO , March 26, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem or the Company) today announced that it
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
08:00am, Thursday, 20'th Mar 2025
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating
Evofem Strengthens SOLOSEC Intellectual Property with New U.S. Patent from USPTO
09:16am, Thursday, 13'th Feb 2025
-- Allowed Patent Extends SOLOSEC IP to 2040 with Broad Claims that are Orange Book-listable -- SAN DIEGO , Feb. 13, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced tha
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
04:36pm, Thursday, 14'th Nov 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged
